Therefore, for patients with pMMR/MSS endometrial cancer, immunosuppressive agents in combination with targeted therapies (e.g., CDK4/6 inhibitors, anti-angiogenic agents) need to be explored to improve efficacy further. The gene discussed is CDK4; the disease is endometrial cancer.